image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - IL
$ 14.0
-2.49 %
$ 16 B
Market Cap
-9.18
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 23, 2025.

The intrinsic value of one TEVA stock under the worst case scenario is HIDDEN Compared to the current market price of 14 USD, Teva Pharmaceutical Industries Limited is HIDDEN

This DCF valuation model was last updated on Apr, 23, 2025.

The intrinsic value of one TEVA stock under the base case scenario is HIDDEN Compared to the current market price of 14 USD, Teva Pharmaceutical Industries Limited is HIDDEN

This DCF valuation model was last updated on Apr, 23, 2025.

The intrinsic value of one TEVA stock under the best case scenario is HIDDEN Compared to the current market price of 14 USD, Teva Pharmaceutical Industries Limited is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TEVA

image
$23.0$23.0$22.0$22.0$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
16.5 B REVENUE
4.40%
-303 M OPERATING INCOME
-69.98%
-1.96 B NET INCOME
-218.54%
1.25 B OPERATING CASH FLOW
-8.85%
792 M INVESTING CASH FLOW
-18.18%
-1.79 B FINANCING CASH FLOW
6.38%
4.23 B REVENUE
-2.38%
-29 M OPERATING INCOME
43.14%
-275 M NET INCOME
37.07%
575 M OPERATING CASH FLOW
-44.28%
202 M INVESTING CASH FLOW
-24.63%
-674 M FINANCING CASH FLOW
0.00%
Balance Sheet Teva Pharmaceutical Industries Limited
image
Current Assets 12.6 B
Cash & Short-Term Investments 3.3 B
Receivables 3.06 B
Other Current Assets 6.19 B
Non-Current Assets 26.8 B
Long-Term Investments 0
PP&E 4.95 B
Other Non-Current Assets 21.8 B
8.39 %7.78 %15.75 %12.58 %55.50 %Total Assets$39.3b
Current Liabilities 12.8 B
Accounts Payable 2.2 B
Short-Term Debt 1.78 B
Other Current Liabilities 8.81 B
Non-Current Liabilities 20.8 B
Long-Term Debt 16.3 B
Other Non-Current Liabilities 4.51 B
6.56 %5.30 %26.22 %48.50 %13.43 %Total Liabilities$33.6b
EFFICIENCY
Earnings Waterfall Teva Pharmaceutical Industries Limited
image
Revenue 16.5 B
Cost Of Revenue 8.48 B
Gross Profit 8.06 B
Operating Expenses 8.37 B
Operating Income -303 M
Other Expenses 1.66 B
Net Income -1.96 B
18b18b16b16b14b14b12b12b10b10b8b8b6b6b4b4b2b2b00(2b)(2b)17b(8b)8b(8b)(303m)(2b)(2b)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
48.74% GROSS MARGIN
48.74%
-1.83% OPERATING MARGIN
-1.83%
-9.91% NET MARGIN
-9.91%
-30.50% ROE
-30.50%
-4.17% ROA
-4.17%
-1.63% ROIC
-1.63%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Teva Pharmaceutical Industries Limited
image
5b5b5b5b4b4b4b4b3b3b3b3b2b2b2b2b1b1b500m500m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -1.96 B
Depreciation & Amortization 1.06 B
Capital Expenditures -498 M
Stock-Based Compensation 123 M
Change in Working Capital -435 M
Others 1.99 B
Free Cash Flow 749 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Teva Pharmaceutical Industries Limited
image
Wall Street analysts predict an average 1-year price target for TEVA of $23.2 , with forecasts ranging from a low of $20 to a high of $28 .
TEVA Lowest Price Target Wall Street Target
20 USD 42.86%
TEVA Average Price Target Wall Street Target
23.2 USD 66.07%
TEVA Highest Price Target Wall Street Target
28 USD 100.00%
Price
Max Price Target
Min Price Target
Average Price Target
282826262424222220201818161614141212Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.085 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.4001.4001.2001.2001.0001.0000.8000.8000.6000.6000.4000.4000.2000.2000.0000.0000.340.340.340.340.340.340.340.340.0850.341.360.341.360.0850.85201520152016201620172017
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Teva Pharmaceutical Industries Limited
image
Sold
0-3 MONTHS
10.9 M USD 5
3-6 MONTHS
6.62 M USD 2
6-9 MONTHS
2.99 M USD 3
9-12 MONTHS
9.56 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now When examined over long stretches, stocks stand atop the pedestal in terms of annualized return, relative to all other asset classes. But this doesn't mean the Dow Jones Industrial Average (^DJI -1.33%), S&P 500 (^GSPC 0.13%), and Nasdaq Composite (^IXIC -0.13%) move from Point A to B in a straight line. fool.com - 1 week ago
Billionaire Sold Broadcom And Bought This Stock That Could Soar 121% TEVA has 121% upside from its share price today. Retiring early is possible, and may be easier than you think. 247wallst.com - 2 weeks ago
5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility For more than a century, the stock market has been the premier wealth creator for investors. But this doesn't mean stocks move higher in a straight line. fool.com - 2 weeks ago
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention PARSIPPANY, N.J. and TEL AVIV, April 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for AJOVY® (fremanezumab-vfrm) to expand the indication to include the prevention of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. If approved, AJOVY would be the only calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, helping to address the high unmet need for effective treatments for those living with migraine. globenewswire.com - 3 weeks ago
New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable PARSIPPANY, N.J. and TEL AVIV, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of a patient and healthcare professional (HCP) attitudes and experiences survey study, complementing the successful Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) evaluating TEV-'749. More than 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very satisfied when asked about TEV-'749, overall, including initiation regimen, monthly dosing schedule and dosing options.1 The data were presented at the 2025 Congress of the Schizophrenia International Research Society (SIRS) taking place from March 29 to April 2, 2025, in Chicago, IL. globenewswire.com - 1 month ago
These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now It's hard to believe, but the first quarter of 2025 is rapidly coming to a close. After doing a quick portfolio checkup, I found that I have stocks that have gained as much as 40% already this year, but I also have a few that are down nearly 30%. fool.com - 1 month ago
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025 TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial results on Wednesday, May 7, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. globenewswire.com - 1 month ago
Teva Releases Q1 2025 Aide Memoire TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the “Investors” page on its website. globenewswire.com - 1 month ago
Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround Stocks Data is abundant, if not overwhelming, on Wall Street. Between earnings season -- the six-week period when a majority of S&P 500 companies unveil their quarterly operating results -- and near-daily economic data releases, it can be easy to miss something important. fool.com - 1 month ago
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings Stanley Druckenmiller, whose net worth is around $6.9 billion, made most of his fortune as a hedge fund manager, and became a well-known name on Wall Street while working for George Soros until 2000. fool.com - 1 month ago
Teva Pharmaceutical Industries Limited (TEVA) Leerink's 2025 Global Healthcare Conference (Transcript) Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Leerink's 2025 Global Healthcare Conference March 12, 2025 8:40 AM ET Company Participants Richard Francis - CEO Unidentified Company Representative Hi. Good morning, everybody. seekingalpha.com - 1 month ago
Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 27th Annual Global Healthcare Conference (Transcript) Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 8:00 AM ET Company Participants Richard Francis - President & CEO Conference Call Participants Balaji Prasad - Barclays Balaji Prasad Good morning, everyone. My name is Balaji Prasad. seekingalpha.com - 1 month ago
8. Profile Summary

Teva Pharmaceutical Industries Limited TEVA

image
COUNTRY IL
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 16 B
Dividend Yield 0.00%
Description Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Contact 124 Dvora Hanevi'a Street, Tel Aviv, 6944020 https://www.tevapharm.com
IPO Date Feb. 16, 1982
Employees 33892
Officers Mr. Christopher J. Stevo CFA Senior Vice President of Investor Relations & Competitive Intelligence Ms. Christine Fox Executive Vice President of U.S. Commercial Business Mr. David R. Mcavoy J.D. Executive Vice President & Chief Legal Officer Mr. Richard D. Francis President, Chief Executive Officer & Director Mr. Amir Weiss Senior Vice President & Chief Accounting Officer Mr. Matthew Shields Executive Vice President of Global Operations Kathleen Veit Senior Vice President, Global Compliance & Ethics Officer Mr. Eliyahu Sharon Kalif Executive Vice President & Chief Financial Officer Mr. Richard Gordon Daniell Executive Vice President of European Commercial Dr. Eric A. Hughes M.D., Ph.D. Executive Vice President of Global R&D and Chief Medical Officer